Basic Information
| Drug ID | DDPD00250 |
|
| Drug Name | Dapsone | |
| Molecular Weight | 248.301 | |
| Molecular Formula | C12H12N2O2S | |
| CAS Number | 80-08-0 | |
| SMILES | NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1 | |
| External Links | ||
| DRUGBANK | DB00250 | |
| T3DB | T3D2482 | |
| PubChem Compound | 2955 | |
| PDR | 261 | |
| Drugs.com | Drugs.com Drug Page | |
Experimental Physicochemical Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Reference |
|---|---|---|---|---|---|
| Log P | 0.97 | - | 0.97 | - | HANSCH,C ET AL. (1995) |
| Melting Point | 175.5 | ℃ | 175.5 | ℃ | DRUGBANK |
| Water Solubility | 380.0 | mg/L | 380 | mg/L | YALKOWSKY,SH & DANNENFELSER,RM 1992) |
| pKa | 2.41 | - | 2.41 | - | PERRIN,DD (1965) |
| Log S | -2.82 | - | -2.82 | - | ADME Research, USCD |
Pharmacokinetic/ Toxicokinetic Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Factor | Reference |
|---|---|---|---|---|---|---|---|
| Bioavailability | 75.0 | % | 70-80 | % | PO, oral; | DRUGBANK | Bioavailability | 93.0 | % | 93±8 | % | PO, oral; | The Pharmacological Basis of Therapeutics | Bioavailability | 75.0 | % | 70-80 | % | PO, oral; leprosy; | leprosy ↓ ; | The Pharmacological Basis of Therapeutics |
| C Max | 1600.0 | ng/ml | 1.6±0.4 | mcg/ml | Oral single dose; adults; normal,healthy; | The Pharmacological Basis of Therapeutics | C Max | 3300.0 | ng/ml | 3.3 | mcg/ml | Oral multiple dose; adults; normal,healthy; | The Pharmacological Basis of Therapeutics |
| T Max | 2.1 | h | 2.1±0.8 | h | Oral single dose; adults; normal,healthy; | The Pharmacological Basis of Therapeutics | |
| Clearance | 0.0360 | L/h/kg | 0.60±0.17 | ml/min/kg | Neonates ↑ ;Children → ;Hepatic cirrhosis, cirr → ; | The Pharmacological Basis of Therapeutics | Clearance | 0.0288 | L/h/kg | 0.48 | ml/min/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Volume of Distribution | 1.0 | L/kg | 1.0±0.1 | L/kg | The Pharmacological Basis of Therapeutics | Volume of Distribution | 0.83 | L/kg | 0.83 | L/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Half-life | 28.0 | h | 28(10-50) | h | DRUGBANK | Half-life | 22.4 | h | 22.4±5.6 | h | Children → ;Hepatic cirrhosis, cirr → ; | The Pharmacological Basis of Therapeutics | Half-life | 22.0 | h | 22 | h | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Toxicity LD50 | 496.0 | mg/kg | 496.0 | mg/kg | PO, oral; mouse; | T3DB | |
| Eliminate Route | 10.0 | % | 5-15 | % | Urinary excretion; Unchanged drug; | The Pharmacological Basis of Therapeutics | |
| Protein Binding | 80.0 | % | 70-90 | % | DRUGBANK | Protein Binding | 73.0 | % | 73±1 | % | RD, renal impairment, Renal disease，including uremia → ;Hepatic cirrhosis, cirr → ; | The Pharmacological Basis of Therapeutics |
Maximum Dosage
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Brand Name | Component | Reference |
|---|---|---|---|---|---|---|---|---|
| Max dose for children | 2.0 | application/day | 2 | application/day | gel | Dapsone | dapsone | PDR |
| Max dose for children | 1.0 | application/day | 1 | application/day | gel | Dapsone | dapsone | PDR |
| Max dose for children | 1.0 | application/day | 1 | application/day | gel | Dapsone | dapsone | PDR |
| Max dose for adolescents | 100.0 | mg/day | 100 | mg/day | PO, oral | Dapsone | dapsone | PDR |
| Max dose for adolescents | 300.0 | mg/day | 300 | mg/day | PO, oral | Dapsone | dapsone | PDR |
| Max dose for adolescents | 200.0 | mg/day | 200 | mg/day | PO, oral | Dapsone | dapsone | PDR |
| Max dose for adolescents | 2.0 | application/day | 2 | application/day | gel | Dapsone | dapsone | PDR |
| Max dose for adolescents | 1.0 | application/day | 1 | application/day | gel | Dapsone | dapsone | PDR |
| Max dose for adults | 100.0 | mg/day | 100 | mg/day | PO, oral | Dapsone | dapsone | PDR |
| Max dose for adults | 300.0 | mg/day | 300 | mg/day | PO, oral | Dapsone | dapsone | PDR |
| Max dose for adults | 200.0 | mg/day | 200 | mg/day | PO, oral | Dapsone | dapsone | PDR |
| Max dose for adults | 2.0 | appLication/day | 2 | appLication/day | gel | Dapsone | dapsone | PDR |
| Max dose for adults | 1.0 | appLication/day | 1 | appLication/day | gel | Dapsone | dapsone | PDR |
| Max dose for geriatric | 100.0 | mg/day | 100 | mg/day | PO, oral | Dapsone | dapsone | PDR |
| Max dose for geriatric | 300.0 | mg/day | 300 | mg/day | PO, oral | Dapsone | dapsone | PDR |
| Max dose for geriatric | 200.0 | mg/day | 200 | mg/day | PO, oral | Dapsone | dapsone | PDR |
| Max dose for geriatric | 2.0 | application/day | 2 | application/day | gel | Dapsone | dapsone | PDR |
| Max dose for geriatric | 1.0 | application/day | 1 | application/day | gel | Dapsone | dapsone | PDR |
Drug Property Radar Chart
Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1